Biopharma Investment Portfolios

Johnson & Johnson Acquires Ambrx Biopharma, Enhancing Cancer Drug Portfolio Amidst Harpoon Therapeutics Advancements Jan 9, 2024

Divergent Trends in U.S. Stocks; Ambrx Biopharma Soars While Crude Oil Declines Jan 9, 2024

Immix Biopharma Strengthens Scientific Advisory Board with Leading AL Amyloidosis Expert Dr. Vaishali Sanchorawala Jan 5, 2024

Enveric Biosciences Reveals Decline in Revenue for Q3 2023 Amid Advancements of Psychedelics into Clinical Trials Nov 15, 2023

Enveric Biosciences Reports Decline in Q3 Revenue as Psychedelic Therapeutics Progress Nov 15, 2023